Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis.

RPEP-115712025Jara, Maximilian; Norlin, Jenny; Kjær, Mette Skalshøi; Almholt, Kasper; Bendtsen, Kristian M; Bugianesi, Elisabetta; Cusi, Kenneth; Galsgaard, Elisabeth D; Geybels, Milan; Gluud, Lise L; Harder, Lea M; Loomba, Rohit; Mazzoni, Gianluca; Newsome, Philip N; Nitze, Louise M; Palle, Mads S; Ratziu, Vlad; Sejling, Anne-Sophie; Wong, Vincent W-S; Anstee, Quentin M; Knudsen, Lotte B

evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis.

Nature medicine, 31(9), 3128-3140

View on PubMed ↗Publisher’s paper ↗

Citation

Jara, Maximilian; Norlin, Jenny; Kjær, Mette Skalshøi; Almholt, Kasper; Bendtsen, Kristian M; Bugianesi, Elisabetta; Cusi, Kenneth; Galsgaard, Elisabeth D; Geybels, Milan; Gluud, Lise L; Harder, Lea M; Loomba, Rohit; Mazzoni, Gianluca; Newsome, Philip N; Nitze, Louise M; Palle, Mads S; Ratziu, Vlad; Sejling, Anne-Sophie; Wong, Vincent W-S; Anstee, Quentin M; Knudsen, Lotte B. (2025). Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis.. Nature medicine, 31(9), 3128-3140. https://doi.org/10.1038/s41591-025-03799-0